The approval was supported by data from 2 randomized, double-blind, vehicle-controlled trials that included 736 patients aged 12 years and older with mild to severe plaque psoriasis of the scalp and ...

You might be experiencing scalp psoriasis if you have itchy, scaly patches and a dry scalp. Psoriasis of the scalp causes inflammation and presents as raised plaques and scales that can itch ...

The FDA approved a supplemental new drug application for roflumilast topical foam 0.3% for the treatment of plaque psoriasis ...

Research led by the SKiN Center for Dermatology observed substantial clearance of scalp and body psoriasis and rapid itch reduction in patients treated with roflumilast foam, 0.3%.

It can even go past your hairline and onto your neck, ears, and forehead. Scalp psoriasis is usually powdery-looking. It may be silver in color. What you can do: Whether your condition is mild ...

Once-daily roflumilast foam, 0.3% (Zoryve) significantly improved scalp and body symptoms of plaque psoriasis in a phase III trial. Improvements in scalp itch were also greater for patients ...

The 0.3% foam formulation of roflumilast was previously approved for the treatment of seborrheic dermatitis in adults and ...

Roflumilast foam 0.3% applied once daily led to significantly greater clearance of scalp and body plaque psoriasis lesions and more rapid itch reduction than placebo over eight weeks.